Association Study of Fat-mass and Obesity-associated Gene and Body Mass Index in Japanese Patients with Schizophrenia and Healthy Subjects

Overview

Journal Clin Psychopharmacol Neurosci

Specialty Psychiatry

Date 2013 Feb 23

PMID 23431037

Citations 4

Authors

Shin-Ya Watanabe

Jun-Ichi Iga

Shusuke Numata

Masahito Nakataki

Toshihito Tanahashi

Mitsuo Itakura

Tetsuro Ohmori

Affiliations

Soon will be listed here.

Abstract

Objective: Fat-mass and obesity-associated (FTO) gene is known to be involved in the pathophysiology of obesity and a single-nucleotide polymorphism (SNP) rs9939609 of FTO gene is repeatedly confirmed to be associated with body mass index (BMI) and obesity. The aim of this study is to elucidate effects of FTO gene polymorphism on BMI in Japanese patients with schizophrenia and healthy subjects.

Methods: Three hundred fifty one patients with schizophrenia and 342 age- and sex-matched healthy subjects participated in the study. Information on BMI and antipsychotic medication was also collected from patients and healthy subjects. Genotype of the FTO SNP rs9939609 was determined by TaqMan SNP Genotyping Assays.

Results: There was no significant difference in BMI between patients and healthy subjects. No significant difference in BMI was observed among any medications. We observed no significant difference in rs9939609 allele frequencies between patients and healthy subjects. There was a significant difference in BMI between healthy subjects with risk (AA or TA) genotypes and those with TT genotype. We also observed a significant positive correlation between the number of risk allele (A allele) and BMI in healthy subjects.

Conclusion: Our study suggested that FTO rs9939609 polymorphism might have some impacts on the BMI in healthy subjects, but might not have same impacts on the BMI of patients with schizophrenia.

Citing Articles

Search for Possible Associations of Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients.

Boiko A, Pozhidaev I, Paderina D, Bocharova A, Mednova I, Fedorenko O Pharmgenomics Pers Med. 2021; 14:1123-1131.

PMID: 34522123 PMC: 8434933. DOI: 10.2147/PGPM.S327353.

Serum Prolactin and Bone Mineral Density in Schizophrenia: A Systematic Review.

Lally J, Bin Sahl A, Murphy K, Gaughran F, Stubbs B Clin Psychopharmacol Neurosci. 2019; 17(3):333-342.

PMID: 31352700 PMC: 6705095. DOI: 10.9758/cpn.2019.17.3.333.

Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia.

Song X, Pang L, Feng Y, Fan X, Li X, Zhang W Behav Brain Funct. 2014; 10(1):35.

PMID: 25278160 PMC: 4282200. DOI: 10.1186/1744-9081-10-35.

Association of obesity with rs1421085 and rs9939609 polymorphisms of FTO gene.

Solak M, Erdogan M, Yildiz S, Ucok K, Yuksel S, Arikan Terzi E Mol Biol Rep. 2014; 41(11):7381-6.

PMID: 25074273 DOI: 10.1007/s11033-014-3627-2.

References

Tabara Y, Osawa H, Guo H, Kawamoto R, Onuma H, Shimizu I . Prognostic significance of FTO genotype in the development of obesity in Japanese: the J-SHIPP study. Int J Obes (Lond). 2009; 33(11):1243-8. DOI: 10.1038/ijo.2009.161. View

Gunes A, Melkersson K, Scordo M, Dahl M . Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol. 2009; 29(1):65-8. DOI: 10.1097/JCP.0b013e31819302c3. View

Frayling T, Timpson N, Weedon M, Zeggini E, Freathy R, Lindgren C . A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007; 316(5826):889-94. PMC: 2646098. DOI: 10.1126/science.1141634. View

Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T . Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry. 2009; 69(9):1416-22. DOI: 10.4088/jcp.v69n0909. View

De Luca V, Mueller D, de Bartolomeis A, Kennedy J . Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol. 2007; 10(5):697-704. DOI: 10.1017/S1461145707007547. View

Lencz T, Robinson D, Napolitano B, Sevy S, Kane J, Goldman D . DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics. 2010; 20(9):569-72. PMC: 2920359. DOI: 10.1097/FPC.0b013e32833ca24b. View

Ikeda M, Aleksic B, Kinoshita Y, Okochi T, Kawashima K, Kushima I . Genome-wide association study of schizophrenia in a Japanese population. Biol Psychiatry. 2010; 69(5):472-8. DOI: 10.1016/j.biopsych.2010.07.010. View

Vimaleswaran K, Li S, Zhao J, Luan J, Bingham S, Khaw K . Physical activity attenuates the body mass index-increasing influence of genetic variation in the FTO gene. Am J Clin Nutr. 2009; 90(2):425-8. DOI: 10.3945/ajcn.2009.27652. View

Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P . Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007; 39(6):724-6. DOI: 10.1038/ng2048. View

10.

Park Y, Chung Y, Lee S, Lee K, Kim H, Byun Y . Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet. 2006; 141B(4):394-7. DOI: 10.1002/ajmg.b.30311. View

11.

Cecil J, Tavendale R, Watt P, Hetherington M, Palmer C . An obesity-associated FTO gene variant and increased energy intake in children. N Engl J Med. 2008; 359(24):2558-66. DOI: 10.1056/NEJMoa0803839. View

12.

Hong C, Liou Y, Bai Y, Chen T, Wang Y, Tsai S . Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010; 20(6):359-66. DOI: 10.1097/FPC.0b013e3283397d06. View

13.

Fredriksson R, Hagglund M, Olszewski P, Stephansson O, Jacobsson J, Olszewska A . The obesity gene, FTO, is of ancient origin, up-regulated during food deprivation and expressed in neurons of feeding-related nuclei of the brain. Endocrinology. 2008; 149(5):2062-71. DOI: 10.1210/en.2007-1457. View

14.

Casey D, Haupt D, Newcomer J, Henderson D, Sernyak M, Davidson M . Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004; 65 Suppl 7:4-18. View

15.

Perez-Iglesias R, Mata I, Amado J, Berja A, Garcia-Unzueta M, Martinez Garcia O . Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment. J Clin Psychopharmacol. 2010; 30(6):661-6. DOI: 10.1097/jcp.0b013e3181fae248. View

16.

Karasawa S, Daimon M, Sasaki S, Toriyama S, Oizumi T, Susa S . Association of the common fat mass and obesity associated (FTO) gene polymorphism with obesity in a Japanese population. Endocr J. 2010; 57(4):293-301. DOI: 10.1507/endocrj.k09e-305. View

17.

Popp J, Leucht S, Heres S, Steimer W . DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J. 2008; 9(1):71-7. DOI: 10.1038/tpj.2008.5. View

18.

Sicard M, Zai C, Tiwari A, Souza R, Meltzer H, Lieberman J . Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics. 2010; 11(11):1561-71. DOI: 10.2217/pgs.10.123. View

19.

Hong C, Lin C, Yu Y, Chang S, Wang S, Tsai S . Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment. Psychiatr Genet. 2002; 12(3):169-71. DOI: 10.1097/00041444-200209000-00009. View

20.

Johnson L, van Jaarsveld C, Emmett P, Rogers I, Ness A, Hattersley A . Dietary energy density affects fat mass in early adolescence and is not modified by FTO variants. PLoS One. 2009; 4(3):e4594. PMC: 2644761. DOI: 10.1371/journal.pone.0004594. View